Cost-benefit analyses (CBA) of every aspect of health and
medical care is necessary to address both the clinical and cost
effectiveness of health and medical care to allocate limited
practitioner, organizational, governmental, and monetary resources.
In response, there is an array of approaches that
emphasize the full continuum of prevention, restructuring
primary care, involvement of the workplace and communities,
and adoption of innovative strategies and interventions,
ranging from genomic assessments to CAM. Among these
approaches is an IM model, which is consistent with these
national objectives of improved health at sustainable cost
with the unique and explicit inclusion of “evidence-based
global medical strategies” in its definition. Although various
forms of preliminary evidence are evolving, all of these strategies
require rigorous,